Selumetinib
Selumetinib is a pharmaceutical drug with 73 clinical trials. Currently 16 active trials ongoing. Historical success rate of 79.2%.
Success Metrics
Based on 38 completed trials
Phase Distribution
Phase Distribution
32
Early Stage
37
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
74.5%
38 of 51 finished
25.5%
13 ended early
16
trials recruiting
73
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
Selumetinib and Olaparib in Solid Tumors
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
Clinical Trials (73)
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
Selumetinib and Olaparib in Solid Tumors
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
AMTEC IIT: Phase 2 Multiarm Study in TNBC
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 73